Korea Investment Corp’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Korea Investment Corp’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-340,870	Closed	-$235K	–	738
2020 Q4	$235K	Hold	340,870	–	–	﹤0.01%	700
2020 Q3	$767K	Hold	340,870	–	–	﹤0.01%	659
2020 Q2	$1.22M	Hold	340,870	–	–	﹤0.01%	662
2020 Q1	$1.29M	Sell	340,870 -281,781	-45%	-$928K	0.01%	640
2019 Q4	$1.87M	Buy	+622,651	New	+$1.62M	0.01%	549

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.82B AUM

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Korea Investment Corp's BMY.RT Position: Q1 2021 in Review

Korea Investment Corp sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 340,870 shares — an estimated $235K sold.

Korea Investment Corp first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $1.87M in Q4 2019. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Korea Investment Corp reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Korea Investment Corp sold 340,870 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $235K.
Korea Investment Corp first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
Korea Investment Corp's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $1.87M in Q4 2019.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Korea Investment Corp's 13F filing for Q1 2021, filed 13 May 2021.